ENA Respiratory Begins Part B Dosing

Melbourne,Australia, 15 September 2026 – ENA Respiratory, a clinical-stage pharmaceutical companydeveloping hostdefence enhancers for theprevention of complications associated with respiratory viral infections inat-risk populations, today announces it has dosed the first participants inPart B of its Phase IIa community study of INNA-051.

INNA-051 is avirus-agnostic, dry powder nasal spray that primes the natural antiviral hostdefences in the nose where common respiratory viruses primarily enter, enabling the body to respond more quickly whenchallenged. INNA-051 therapy aims to reduce the incidence of complications inpatients at higher risk of severe illness.

The ‘POSITS’ study (NCT07222670) is evaluating the safety, tolerability and efficacy of upto three months’ treatment with INNA-051 and assessing its impact on theincidence, duration and severity of symptomatic infections caused by commonrespiratory viruses, including influenza, RSV, rhinovirus, and coronaviruses inyoung adult participants at risk of illness due to living or working in crowdedenvironments

Part A of the study was successfully completed in 200 participants in May with no safety concernsidentified following four weeks of weekly dosing.

Part B will recruit up to 900participants during this North American respiratory virus season, withparticipants dosed for three months across five sites in the USA, including theCenter for Vaccine Development and Global Health (CVD) at the University ofMaryland, Baltimore, the Naval Medical Research Command (NMRC) Clinical TrialsCenter, Bethesda, Maryland and three Accellacare clinical sites in NorthCarolina. Recruitment will continue to target those in severely crowdedhouseholds, residents of university housing, military personnel living inbarracks, childcare center workers and/or those living with or caring for achild aged 10 or less attending school or day care (https://enarespiratory.com/inna-051/clinical-trials/).

‍

‍ENA Respiratory’s Consultant MedicineDevelopment Lead, Ruth Tal-Singer, PhD said: “The start of large Part B of our study is another importantmilestone in the development of INNA-051. Complications from respiratory viralinfections continue to place a huge burden on patients and healthcare systemsglobally. By boosting the body’s natural host defence pathways, we believeINNA-051 could offer new hope to millions of vulnerable patients worldwide andwe look forward to adding to the clinical evidence of its potential throughthis study.”

‍

About ENA Respiratory

ENARespiratory is a clinical-stage pharmaceutical company developing antiviralhost defence enhancers for the prevention of severe complications fromrespiratory viral infections in at-risk populations.

ENA’s approach offers a virus-agnostic solution toprotect against common and emerging respiratory viruses for which vaccines ordirect-acting antivirals have limitations or do not exist. Itis an alumni member of BLUE KNIGHT™, a jointinitiative between Johnson & Johnson Innovation and BARDA designed toaccelerate novel potential solutions for future pandemics.

The Company’s clinical program includes a Phase IIacommunity study (NCT07222670) currently in progress inthe US evaluating safety, tolerability and efficacy in young adults at risk ofrespiratory viral illness owing to living or working in crowded environments. Afurther Phase I clinical study is planned in asthma patients in Australia.

Headquartered in Melbourne, Australia, withoperations in the USA, ENA’s Investors include Brandon Capital, Flu Lab, theGates Foundation, the Minderoo Foundation, Stoic Venture Capital and Uniseed.The Company has been awarded funding contracts from the U.S. Government, andAustralia’s CUREator and Biointelect Venturerprograms.

For more information, please visit https://enarespiratory.com

Follow us on LinkedIn: https://www.linkedin.com/company/enarespiratory-pty-ltd/

For moreinformation, please visit https://enarespiratory.com

Follow uson LinkedIn: https://www.linkedin.com/company/enarespiratory-pty-ltd/

For further information, please contact:

Media –International

Charles Consultants

SueCharles, E: Sue.charles@charles-consultants.com M: +44 (0)7968 726585 

Chris Gardner, E: Chris@CGComms.onmicrosoft.com M: +44 (0)7956 03107

Media – Australia

Ruth Heenan, E: rheenan@bcpvc.com  M: +61 (0)416 565 332